HYDROCHLOROTHIAZIDE
| Brand name | INZIRQO |
|---|---|
| Active ingredient | HYDROCHLOROTHIAZIDE |
| Strength | 10MG/ML |
| Dosage form | FOR SUSPENSION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | January 2025 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11878022 | January 2044 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.